7 Nov 2012 07:00
07 November 2012
Embargoed for 07:00
Instem plc
("Instem", the "Company" or the "Group")
Contract Win with U.S. Government Research Agency
Provantis Preclinical Software Chosen to Advance Key NIAID Research Programs
Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has selected Instem's integrated Provantis® preclinical software suite to help advance research programs against infectious, immunologic, and allergic diseases.
Provantis is being deployed within U.S. based laboratories where NIAID conducts basic and applied research activities aimed at improving public health in the United States and around the world.
Phil Reason, CEO of Instem plc, commented: "It is a great affirmation of Instem's products that another US Government Agency has selected our software. The award of this contract is very exciting for Instem as the NIH invests over $30.9 billion annually in medical research and Instem has been actively targeting institutions and projects directly or indirectly funded from this budget."
For further information, please contact:
Instem plc | +44 (0) 1785 825 600 |
Phil Reason, CEO | |
Nigel Goldsmith, CFO | |
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 3205 7500 |
Aubrey Powell | |
Joe Stroud | |
Newgate Threadneedle | +44 (0) 20 7653 9850 |
Caroline Evans-Jones | |
Fiona Conroy |
About Instem plc
Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China, India and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.
To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.
INS.L (INS)